We are live on ! Find out more
OPPM

Opus Point Partners Management Portfolio holdings

AUM $55.3M Turnover 18.46%
1-Year Est. Return 7.48%
This Fund
S&P 500
This Quarter Est. Return
+17.69%
1 Year Est. Return
-7.48%
3 Year Est. Return
+85.18%
5 Year Est. Return
+168.21%
10 Year Est. Return
–
AUM
$135M
AUM Growth
+$9.21M
Cap. Flow
+$6.26M
Cap. Flow %
4.65%
Top 10 Hldgs %
39.93%
Holding
69
New
12
Increased
31
Reduced
2
Closed
2
Avg Time Held Equity + Options
0.9 years
Top 10 Avg Time Held Equity + Options
0.5 years
Top 20 Avg Time Held Equity + Options
0.9 years
Avg Time Held Equity only
1 year
Top 10 Avg Time Held Equity only
0.7 years
Top 20 Avg Time Held Equity only
0.9 years

Top Buys

Rank Stock Value
1
QGEN icon
Qiagen
QGEN
+$3.25M
2
AXSM icon
Axsome Therapeutics
AXSM
+$1.28M
3
HRTX icon
Heron Therapeutics
HRTX
+$439K
4
PGNX
Progenics Pharmaceuticals Inc
PGNX
+$435K
5
SCYX icon
SCYNEXIS
SCYX
+$419K

Top Sells

Rank Stock Value
1
QGENF
QIAGEN NV
QGENF
+$3.13M
2
ALXN
Alexion Pharmaceuticals
ALXN
+$809K
3
LABU icon
Direxion Daily S&P Biotech Bull 3X ETF
LABU
+$249K

Sector Composition

Rank Sector Weight
1 Healthcare 77.47%
2 Miscellaneous 21.89%
3 Real Estate 0.63%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
IOVA icon
51
Iovance Biotherapeutics
IOVA
$6.67B
$396K 0.29%
53,157
+14,210
+36% +$104K
2016 Q2
3 quarters
LGND icon
52
Ligand Pharmaceuticals
LGND
$5.95B
$394K 0.29%
5,962
+1,812
+44% +$119K
2016 Q4
1 quarter
MYGN icon
53
Myriad Genetics
MYGN
$416M
$393K 0.29%
20,484
+6,577
+47% +$117K
2016 Q4
1 quarter
GILD icon
54
Gilead Sciences
GILD
$195B
$390K 0.29%
5,737
+2,329
+68% +$164K
2016 Q4
1 quarter
AKBA icon
55
Akebia Therapeutics
AKBA
$193M
$387K 0.29%
+42,019
New +$410K
2017 Q1
0 quarters
TECH icon
56
Bio-Techne
TECH
$11.4B
$385K 0.29%
15,160
+5,292
+54% +$137K
2016 Q4
1 quarter
ACAD icon
57
Acadia Pharmaceuticals
ACAD
$3.4B
$383K 0.28%
11,130
+1,088
+11% +$38.4K
2016 Q4
1 quarter
AVXS
58
DELISTED
AveXis, Inc. Common Stock
AVXS
$380K 0.28%
5,000
– –
2016 Q4
1 quarter
ICPT
59
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
$375K 0.28%
3,312
+1,177
+55% +$137K
2016 Q3
2 quarters
UTHR icon
60
United Therapeutics
UTHR
$23.2B
$373K 0.28%
2,756
+805
+41% +$122K
2014 Q4
9 quarters
ALDR
61
DELISTED
Alder Biopharmaceuticals
ALDR
$371K 0.28%
+17,858
New +$395K
2017 Q1
0 quarters
SCYX icon
62
SCYNEXIS
SCYX
$38.9M
$368K 0.27%
+1,665
New +$419K
2017 Q1
0 quarters
PGEN icon
63
Precigen
PGEN
$2.58B
$365K 0.27%
18,411
+8,447
+85% +$189K
2016 Q4
1 quarter
BIVV
64
DELISTED
Bioverativ Inc. Common Stock
BIVV
$304K 0.23%
+5,587
New +$275K
2017 Q1
0 quarters
SIOX
65
DELISTED
Sio Gene Therapies Inc. Common Stock
SIOX
$260K 0.19%
+2,178
New +$228K
2017 Q1
0 quarters
STML
66
DELISTED
Stemline Therapeutics, Inc.
STML
$176K 0.13%
+20,595
New +$188K
2017 Q1
0 quarters
MCRB icon
67
Seres Therapeutics
MCRB
$25.4M
$158K 0.12%
700
– –
2015 Q4
5 quarters
XBI icon
68
CALL
State Street SPDR S&P Biotech ETF
XBI
$9.9B
– –
-300,000
Closed -$17.8M –
QGENF
69
DELISTED
QIAGEN NV
QGENF
– –
-111,683
Closed -$3.13M –
1 2
3

Similar funds

KIA
Kopp Investment Advisors Bloomington, Minnesota $54.4M AUM 14.33% 1-Year Est. Return
PGA
Premia Global Advisors Coral Gables, Florida $57.9M AUM 2.91% 1-Year Est. Return
GX
Greylock XII Menlo Park, California $51.9M AUM 11.52% 1-Year Est. Return
SCG
Saban Capital Group Los Angeles, California $59.5M AUM 3.83% 1-Year Est. Return
TCMV
Technology Crossover Management VI Menlo Park, California $59.6M AUM 18.81% 1-Year Est. Return
FCM
Farmstead Capital Management Ridgewood, New Jersey $49M AUM 10.57% 1-Year Est. Return
DP
DW Partners New York $62.3M AUM 25.52% 1-Year Est. Return
SAM
Sheffield Asset Management Chicago, Illinois $48.1M AUM 12.96% 1-Year Est. Return

Opus Point Partners Management's Q1 2017 Portfolio in Review

As of Q1 2017, Opus Point Partners Management held 69 positions worth $135M, up 7.3% from $126M the previous quarter. Its ten largest holdings account for 40% of the portfolio.

Opus Point Partners Management deployed $6.26M of net new capital in Q1 2017, opening 12 new positions and adding to 31 existing holdings. Its largest new stake was Qiagen: 105,399 shares worth $3.24M.

By sector, the portfolio is most concentrated in Healthcare at 77% of assets, up from 65% a quarter earlier, followed by Miscellaneous and Real Estate.

On the sell side, the largest reduction was Alexion Pharmaceuticals, an estimated $809K trimmed.

  • Opus Point Partners Management's largest Q1 2017 buy was Qiagen: 105,399 shares worth $3.24M.
  • Opus Point Partners Management added most to Precigen in Q1 2017, an estimated $189K increase.
  • Opus Point Partners Management's biggest Q1 2017 reduction was Alexion Pharmaceuticals, cutting an estimated $809K.
  • Opus Point Partners Management fully exited QIAGEN NV in Q1 2017, selling an estimated $3.13M.
  • Opus Point Partners Management's ten largest holdings make up 40% of its $135M portfolio in Q1 2017.
  • Opus Point Partners Management opened 12 new positions and closed 2 in Q1 2017.
  • Opus Point Partners Management's portfolio value rose 7.3% quarter-over-quarter to $135M.

Based on Opus Point Partners Management's 13F filing for Q1 2017, filed 15 May 2017.